Clinicians Clinical explainer

Obesity & liver health

Originally posted Sep 2026 · By Joe Zucchi, PA-C, MPAS

Download JPG ↓Original LinkedIn post ↗

1280 × 1600 px · PDF includes the original image and a link to this page.

Joe’s commentary

About this visual

Connecting adipose tissue, metabolic health, MASLD, and MASH.

When we think about obesity, we need to think about the liver too.

In obesity medicine, we spend a lot of time talking about A1c, blood pressure, cholesterol, cardiovascular risk, and sleep apnea. But liver health still does not get enough attention.

MASLD, or metabolic dysfunction-associated steatotic liver disease, affects 1 in 3 U.S. adults and is especially common in people living with obesity, insulin resistance, and type 2 diabetes.

It is also very underdiagnosed. In one large U.S. analysis, MASLD was identified in less than 1% of patients annually using diagnostic codes.

Visceral and ectopic fat are not just passive energy storage. Dysfunctional adipose tissue contributes to insulin resistance, free fatty acid overflow, and inflammatory signaling. When excess fat accumulates in the liver, it can contribute to steatosis, inflammation, cellular injury, and eventually fibrosis.

MASLD is also not just a liver problem. Cardiovascular disease is the leading cause of death among people with MASLD, which is why liver health needs to be part of the cardiometabolic conversation.

The good news is that screening can be easy.

For many at-risk patients, a simple first step is the FIB-4 score, which uses age, AST, ALT, and platelet count. Current guidance recommends fibrosis risk assessment particularly in patients with type 2 diabetes, overweight or obesity plus another metabolic risk factor, or incidentally identified hepatic steatosis or elevated liver enzymes.

If FIB-4 is elevated, additional noninvasive testing such as FibroScan or an ELF blood test may be appropriate.

This is another reason obesity treatment should go far beyond the number on the scale. We should be thinking about visceral fat, liver fat, cardiovascular risk, glycemic health, muscle preservation, kidney health, and the long-term complications of metabolic disease.

The treatment options for MASH are changing quickly too. Novo Nordisk's Wegovy and Madrigal Pharmaceuticals's Rezdiffra now have FDA-approved indications for adults with noncirrhotic MASH and moderate-to-advanced fibrosis, while investigational therapies including Boehringer Ingelheim's survodutide and Eli Lilly and Company's retatrutide are being studied in late-stage trials.

When we treat obesity, we should not just ask what is happening on the scale. We should also ask what is happening metabolically inside.

For many patients, that should include thinking about the liver.

Sources & further reading

Original LinkedIn post and discussion ↗

Additional references appear in the infographic and the original LinkedIn discussion.

Related visuals

Obesity & liver health

Pinch to zoom on touch devices. Open full image ↗